Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Sycamore Partners up to $23.7 billion acquisition of Walgreens Boots Alliance
We are advising Sycamore Partners on the transaction
Tenaya Therapeutics $52.5 million units offering
The units comprise common stock and warrants
Denali Therapeutics $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Haleon $3 billion secondary placing of ordinary shares
The private placement included 700,000,000 ordinary shares
AbbVie $4 billion senior notes offering
The investment-grade notes are due 2028, 2030, 2035 and 2055
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
NeuroPace $74.75 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market